Article ID Journal Published Year Pages File Type
2140178 Leukemia Research 2006 7 Pages PDF
Abstract

For refractory and early relapsed AML, this prospective phase II clinical trial evaluated a salvage chemotherapy regimen, which was consisted of continuous infusion intermediate-dose cytarabine (1 g/m2/day, 24 h i.v. infusion × 5), mitoxantrone (12 mg/m2/day × 3), and etoposide (150 mg/m2/day × 3). We treated 33 patients and 17 (51.5%) achieved CR with a median duration of 117 days. Median overall survival was 219 days. Our results suggest that continuous infusion intermediate-dose cytarabine, together with mitoxantrone and etoposide, may induce CR in a significant proportion of patients with refractory or early relapsed AML, although remission duration was short.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Authors
, , , , , , , , , , , ,